Fennec Pharmaceuticals Plans Upcoming Financial Results Call

Fennec Pharmaceuticals Announces Financial Results Date

Fennec Pharmaceuticals Inc. (NASDAQ: FENC), a specialized pharmaceutical entity, has officially set the date for its second quarter financial results report. This essential update is scheduled for release before the U.S. markets open on a Thursday in August. The financial results will reflect the company's ongoing commitment to addressing the challenges faced by cancer patients.

Conference Call Details

On the day of the report, the management team will conduct a conference call and webcast to discuss the details surrounding the financial results and the broader business implications. This interactive session is an excellent opportunity for stakeholders to gain insights directly from the team.

Call Information

Date: Thursday, August 14
Time: 8:30 a.m. Eastern Time

How to Join

To access the conference call, participants can visit the investor section of Fennec’s website. It’s advisable to log on at least 15 minutes before the call starts to address any technical requirements needed for participating in the webcast.

Fennec Pharmaceuticals Overview

Committed to enhancing the lives of cancer patients, Fennec Pharmaceuticals focuses on solutions to mitigate the significant risks associated with cisplatin-induced hearing loss, also known as ototoxicity. Their flagship product, PEDMARK, is designed to protect patients from this serious side effect of chemotherapy.

Recent Developments in Commercialization

PEDMARK achieved FDA approval in September 2022 and was subsequently approved by the European Commission in June 2023, making it a pivotal development for the company. Moreover, in a move to expand its market presence, Fennec entered into a licensing agreement enabling Norgine Pharmaceuticals Ltd. to manage the commercialization of PEDMARQSI in targeted regions such as Europe and the U.K.

Regulatory Advancements

The company has received Orphan Drug Exclusivity in the U.S. for PEDMARK. Furthermore, the European market recognizes PEDMARQSI's Pediatric Use Marketing Authorization, which grants extensive data protection, illustrating the drug’s potential impact on pediatric cancer patients.

Intellectual Property Protection

Fennec’s innovation is safeguarded by patents extending until 2039, ensuring that their groundbreaking work and contributions to cancer treatment remain protected. This strategic advantage positions Fennec as a leader in this vital aspect of patient care.

Investor Engagement and Contact Information

Fennec Pharmaceuticals reminds interested parties to stay connected for future updates. For more information about the company and its latest efforts, visit their official website and stay updated with their news releases.

Contact for Investors

For inquiries, please reach out to:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Media Relations

For media inquiries:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com

Frequently Asked Questions

What are Fennec Pharmaceuticals' main products?

Fennec Pharmaceuticals focuses on the commercialization of PEDMARK, aimed at reducing hearing loss in cancer patients undergoing treatment.

When will Fennec Pharmaceuticals release its financial results?

The financial results for the second quarter are scheduled to be released before the U.S. markets open on August 14.

How can investors participate in the conference call?

Investors can join the call by visiting Fennec's website and accessing the investor section prior to the event.

What recent approvals has PEDMARK received?

PEDMARK received FDA approval in September 2022 and was also granted approval by the European Commission in June 2023.

Who should I contact for investor inquiries?

For investor inquiries, please contact Robert Andrade, the CFO at Fennec Pharmaceuticals.

About The Author

Dominic Sanders here, a writer and financial specialist committed to helping my readers understand the world of finance. Having a strong financial background and a lot of experience, I concentrate on using my blog posts and articles to translate difficult financial subjects into understandable, doable advice. My goal in writing is to arm you with the information and skills need to make wise financial choices.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors seeking new perspectives to seasoned investors. My mission is to make money understandable and approachable so you may confidently take charge of your financial future. I appreciate you walking this road with me to success and financial literacy.

Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.